Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00616642 · ADVERSE EVENTS

Adverse events

Rosiglitazone in Treating Patients With Pituitary Tumors · Source last updated 2020-08-14

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Adverse events occurred during the study; they are not necessarily caused by treatment. Serious events are not interchangeable with severe/grade 3–4 events. These safety populations may differ from efficacy populations.

Collection time frame
Not reported
Other-event reporting threshold
5%
Participants affected / participants at risk, as reported
Safety groupSerious eventsOther eventsDeaths
Group 1 (ACTH-secreting Adenomas)

Patients receive 4 mg oral rosiglitazone maleate once daily in week 1 and then 8 mg once daily beginning in week 2 and continuing for up to 6 months in the absence of disease progression or unacceptable toxicity. rosiglitazone maleate : Given orally

0 / 00 / 0Not reported / Not reported
Group 2 (Non-secreting Macroadenomas)

Patients receive 4 mg oral rosiglitazone maleate once daily in week 1 and then 8 mg once daily beginning in week 2 and continuing for up to 12 months in the absence of disease progression or unacceptable toxicity. rosiglitazone maleate : Given orally

0 / 10 / 1Not reported / Not reported

Group identifiers: EG000: Group 1 (ACTH-secreting Adenomas) · EG001: Group 2 (Non-secreting Macroadenomas)

Serious adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

    Other reported adverse events

    Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

      Complete source fields
      event Groups
      1. description
        Patients receive 4 mg oral rosiglitazone maleate once daily in week 1 and then 8 mg once daily beginning in week 2 and continuing for up to 6 months in the absence of disease progression or unacceptable toxicity. rosiglitazone maleate : Given orally
        id
        EG000
        other Num Affected
        0
        other Num At Risk
        0
        serious Num Affected
        0
        serious Num At Risk
        0
        title
        Group 1 (ACTH-secreting Adenomas)
      2. description
        Patients receive 4 mg oral rosiglitazone maleate once daily in week 1 and then 8 mg once daily beginning in week 2 and continuing for up to 12 months in the absence of disease progression or unacceptable toxicity. rosiglitazone maleate : Given orally
        id
        EG001
        other Num Affected
        0
        other Num At Risk
        1
        serious Num Affected
        0
        serious Num At Risk
        1
        title
        Group 2 (Non-secreting Macroadenomas)
      frequency Threshold
      5

      Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

      Preserved source evidence · Not medical advice